Edelson Lechtzin LLP Investigates PetMed Express Inc. for Securities Violations

Investigation into PetMed Express, Inc. (NASDAQ: PETS)

Edelson Lechtzin LLP, a leading national law firm specializing in class actions, has announced a thorough investigation into PetMed Express, Inc. (NASDAQ: PETS). This inquiry is centered around potential breaches of federal securities laws, specifically concerning claims of misleading information disseminated to investors. The past few months have witnessed troubling signs for PetMed, which raises questions about the integrity of its financial disclosures.

Background of PetMed Express, Inc.

Founded in 1996, PetMed Express has carved out a niche as a prominent online pet pharmacy. The company offers a wide array of products that include medications, supplements, and health-related items for pets. With its convenient online platform, PetMed has gained substantial popularity among pet owners. However, recent developments have put a spotlight on its operations, stirring concerns among stakeholders.

Allegations of Misleading Information

Amid significant corporate developments, PetMed issued a startling announcement on June 10, 2025, indicating a delay in releasing its financial results for the fourth quarter and entire fiscal year of 2025. The company cited the complexity involved in completing its year-end audit as the reason for this postponement. As a direct consequence of this announcement, PetMed's stock experienced a sharp decline, plummeting by 11.22% on June 11, closing at $3.72.

This downturn in stock price was further exacerbated when, on July 1, 2025, PetMed revealed it could not file its fiscal 2025 Annual Report on time due to ongoing internal reviews regarding revenue recognition practices. This delay caused the stock price to drop another 1.51%, closing at $3.27 that day.

The situation escalated on November 12, 2025, when PetMed announced it would also be late in submitting its third-quarter 2025 Form 10-Q. This announcement was linked to the previously delayed report and the subsequent investigation by the Audit Committee. Following this revelation, the company's stock suffered a sizable blow, falling by 32.41% to close at just $1.96 on November 13, 2025.

Legal Implications

The recent price drops in PetMed's shares, coupled with the company's failure to meet crucial financial reporting deadlines, warrant scrutiny under federal securities laws. In light of these events, Edelson Lechtzin is reaching out to investors who have faced any losses as a result of these developments, encouraging them to provide accounts or insights that may aid in the investigation.

What Should Affected Investors Do?

If you are a shareholder of PetMed Express and feel that you have experienced significant financial losses due to the company's actions or inactions, you are encouraged to contact Edelson Lechtzin LLP. The firm's attorneys are ready to assist and can be reached at 844-563-5550 or via email at [email protected].

About Edelson Lechtzin LLP

Edelson Lechtzin LLP stands out as a prominent class action law firm with offices in Pennsylvania and California. The firm's expertise extends beyond securities fraud to various legal areas, including antitrust violations, wage disputes, and consumer fraud. With a commitment to protecting consumer rights and pursuing justice, Edelson Lechtzin LLP has built a robust reputation in advocating on behalf of harmed investors.

In conclusion, the current investigation emphasizes the critical importance of accountability and transparency in corporate governance, particularly for publicly-listed companies. As the investigation unfolds, stakeholders are advised to stay informed and be vigilant in their investments.